Last reviewed · How we verify
FOLFOX4 or XELOX
FOLFOX4 and XELOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluoropyrimidine and platinum-based cytotoxic agents.
FOLFOX4 and XELOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluoropyrimidine and platinum-based cytotoxic agents. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colorectal cancer, Gastric cancer.
At a glance
| Generic name | FOLFOX4 or XELOX |
|---|---|
| Sponsor | Federation Francophone de Cancerologie Digestive |
| Drug class | Combination chemotherapy (fluoropyrimidine + platinum agent) |
| Target | Thymidylate synthase (5-FU/capecitabine); DNA (oxaliplatin cross-linking) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFOX4 combines 5-fluorouracil (5-FU), leucovorin, and oxaliplatin; XELOX substitutes oral capecitabine for intravenous 5-FU. Both regimens work synergistically: 5-FU/capecitabine inhibit thymidylate synthase to disrupt DNA synthesis, while oxaliplatin forms DNA cross-links. These agents target rapidly dividing cancer cells across multiple phases of the cell cycle.
Approved indications
- Metastatic colorectal cancer
- Adjuvant treatment of stage III colorectal cancer
- Gastric cancer
- Pancreatic cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Peripheral neuropathy
- Anemia
- Thrombocytopenia
- Hand-foot syndrome (XELOX)
Key clinical trials
- Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over (PHASE3)
- Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer (PHASE3)
- Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers (PHASE3)
- Yiqi Wenjing Prescriptions Preventive Efficacy of Oxaliplatin-induced Peripheral Neuropathy Clinical Trial (PHASE3)
- Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer (PHASE3)
- FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer (PHASE3)
- Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer (PHASE3)
- Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOLFOX4 or XELOX CI brief — competitive landscape report
- FOLFOX4 or XELOX updates RSS · CI watch RSS
- Federation Francophone de Cancerologie Digestive portfolio CI